| Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo … TF Dejgaard, CS Frandsen, TS Hansen, T Almdal, S Urhammer, ... The lancet Diabetes & endocrinology 4 (3), 221-232, 2016 | 151 | 2016 |
| Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men SH Knudsen, LS Hansen, M Pedersen, T Dejgaard, J Hansen, GV Hall, ... Journal of applied physiology 113 (1), 7-15, 2012 | 122 | 2012 |
| Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus CS Frandsen, TF Dejgaard, S Madsbad The Lancet Diabetes & Endocrinology 4 (9), 766-780, 2016 | 105 | 2016 |
| Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind … CS Frandsen, TF Dejgaard, JJ Holst, HU Andersen, B Thorsteinsson, ... Diabetes care 38 (12), 2250-2257, 2015 | 91 | 2015 |
| Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial NJ Johansen, TF Dejgaard, A Lund, C Schlüntz, CS Frandsen, JL Forman, ... The Lancet Diabetes & Endocrinology 8 (4), 313-324, 2020 | 44 | 2020 |
| The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised … K Faerch, MB Blond, L Bruhn, H Amadid, D Vistisen, KKB Clemmensen, ... Diabetologia 64, 42-55, 2021 | 39 | 2021 |
| Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: the lira pump trial—a randomized, double … TF Dejgaard, S Schmidt, CS Frandsen, D Vistisen, S Madsbad, ... Diabetes, Obesity and Metabolism 22 (4), 492-500, 2020 | 38 | 2020 |
| Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy T Hvid, K Winding, A Rinnov, T Dejgaard, C Thomsen, P Iversen, ... Endocrine-related cancer 20 (5), 621-632, 2013 | 37 | 2013 |
| Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo … CS Frandsen, TF Dejgaard, HU Andersen, JJ Holst, B Hartmann, ... Diabetes, Obesity and Metabolism 19 (6), 773-782, 2017 | 32 | 2017 |
| Duration and complications of diabetes mellitus and the associated risk of infective endocarditis L Østergaard, UM Mogensen, JS Bundgaard, A Dahl, A Wang, ... International Journal of Cardiology 278, 280-284, 2019 | 25 | 2019 |
| Emerging drugs for the treatment of obesity C Martinussen, KN Bojsen-Moller, MS Svane, TF Dejgaard, S Madsbad Expert opinion on emerging drugs 22 (1), 87-99, 2017 | 23 | 2017 |
| Liraglutide for treating type 1 diabetes TF Dejgaard, CS Frandsen, JJ Holst, S Madsbad Expert Opinion on Biological Therapy 16 (4), 579-590, 2016 | 22 | 2016 |
| Non-insulin pharmacological therapies for treating type 1 diabetes CS Frandsen, TF Dejgaard, S Madsbad, JJ Holst Expert Opinion on Pharmacotherapy 19 (9), 947-960, 2018 | 19 | 2018 |
| Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a … TF Dejgaard, FK Knop, L Tarnow, CS Frandsen, TS Hansen, T Almdal, ... BMJ open 5 (4), e007791, 2015 | 18 | 2015 |
| The efficacy and safety of exenatide once weekly in patients with type 2 diabetes SM Heimbürger, A Brønden, NJ Johansen, TF Dejgaard, T Vilsbøll, ... Expert Opinion on Pharmacotherapy 20 (5), 501-510, 2019 | 17 | 2019 |
| Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials TF Dejgaard, BJ von Scholten, E Christiansen, FF Kreiner, L Bardtrum, ... Diabetes, Obesity and Metabolism 23 (12), 2752-2762, 2021 | 16 | 2021 |
| Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes L Østergaard, CS Frandsen, TF Dejgaard, S Madsbad Expert Review of Clinical Pharmacology 10 (6), 621-632, 2017 | 15 | 2017 |
| Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy J Fleischer, E Laugesen, SL Cichosz, P Hoeyem, TF Dejgaard, ... Journal of Diabetes and its Complications 31 (9), 1389-1393, 2017 | 14 | 2017 |
| Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes TF Dejgaard, NB Johansen, CS Frandsen, A Asmar, L Tarnow, FK Knop, ... Diabetes, Obesity and Metabolism 19 (5), 734-738, 2017 | 14 | 2017 |
| Glycemic control and variability of diabetes secondary to total pancreatectomy assessed by continuous glucose monitoring CTB Juel, TF Dejgaard, CP Hansen, JH Storkholm, T Vilsbøll, A Lund, ... The Journal of Clinical Endocrinology & Metabolism 106 (1), 168-173, 2021 | 13 | 2021 |
